{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T15:28:19Z","timestamp":1771946899240,"version":"3.50.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Baclofen may reduce the symptoms of alcohol withdrawal, as an alternative or as an adjuvant for benzodiazepines, but the available data are insufficient to support baclofen-assisted alcohol withdrawal. This study investigated the need for diazepam during acute alcohol withdrawal in patients receiving baclofen. In a single-blind, dose-dependent randomized controlled trial with three study arms, 63 patients with alcohol use disorder, starting in-patient benzodiazepine-assisted alcohol detoxification, were randomly assigned to receive placebo (n\u00a0=\u200918), baclofen 30\u00a0mg\/day (N\u00a0=\u200920), or baclofen 60\u00a0mg\/day (N\u00a0=\u200925) for 7 days. Diazepam was provided as needed based on the withdrawal symptoms stated by Clinical Institute Withdrawal Assessment for Alcohol-revised. The primary outcome measure was the number of patients in need of diazepam during alcohol detoxification. Secondary outcome measure included the between-group difference in the amount of diazepam needed during alcohol detoxification. Using baclofen 60\u00a0mg\/day, 32% of patients needed additional diazepam compared to 35% on baclofen 30\u00a0mg\/day and compared to 72% on placebo (P\u00a0=\u2009.013). The median total amount of diazepam needed was significantly lower in patients receiving baclofen 60\u00a0mg\/day (0\u2009\u00b1\u200910\u00a0mg diazepam) and baclofen 30\u00a0mg\/day (0\u2009\u00b1\u200910\u00a0mg diazepam) compared to placebo (10\u2009\u00b1\u200943\u00a0mg diazepam; P\u00a0=\u2009.017). Adverse events were comparable between patients on baclofen and placebo. Baclofen can reduce the withdrawal symptoms during alcohol detoxification. Baclofen was well tolerated and may be considered for the management of alcohol withdrawal syndrome, especially useful in situations where benzodiazepines should be withheld, such as patients with liver impairment.<\/jats:p>","DOI":"10.1093\/alcalc\/agad050","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T09:16:08Z","timestamp":1690881368000},"page":"565-569","source":"Crossref","is-referenced-by-count":4,"title":["Baclofen during alcohol detoxification reduces the need for additional diazepam: a randomized placebo-controlled trial"],"prefix":"10.1093","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8798-0448","authenticated-orcid":false,"given":"Cleo L","family":"Crunelle","sequence":"first","affiliation":[{"name":"Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel) Department of Psychiatry, , Laarbeeklaan 101, Brussels 1090 , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Jegham","sequence":"additional","affiliation":[{"name":"Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel) Department of Psychiatry, , Laarbeeklaan 101, Brussels 1090 , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Vanderbruggen","sequence":"additional","affiliation":[{"name":"Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel) Department of Psychiatry, , Laarbeeklaan 101, Brussels 1090 , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frieda","family":"Matthys","sequence":"additional","affiliation":[{"name":"Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel) Department of Psychiatry, , Laarbeeklaan 101, Brussels 1090 , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,7,31]]},"reference":[{"key":"2023091106383942000_ref1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0002-9343(01)01088-9","article-title":"Rapid suppression of alcohol withdrawal syndrome by baclofen","volume":"112","author":"Addolorato","year":"2002","journal-title":"Am J Med"},{"key":"2023091106383942000_ref2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/00002826-200309000-00010","article-title":"Suppression of alcohol delirium tremens by baclofen administration: a case report","volume":"26","author":"Addolorato","year":"2003","journal-title":"Clin Neuropharmacol"},{"key":"2023091106383942000_ref3","doi-asserted-by":"crossref","first-page":"276.e13","DOI":"10.1016\/j.amjmed.2005.08.042","article-title":"Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam","volume":"119","author":"Addolorato","year":"2006","journal-title":"Am J Med"},{"key":"2023091106383942000_ref4","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"key":"2023091106383942000_ref5","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/alcalc\/agr017","article-title":"Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Addolorato","year":"2011","journal-title":"Alcohol Alcohol"},{"key":"2023091106383942000_ref6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s13311-019-00802-8","article-title":"Diagnosis and management of alcohol use disorder in patients with liver disease: lights and shadows","volume":"17","author":"Addolorato","year":"2020","journal-title":"Neurotherapeutics"},{"key":"2023091106383942000_ref7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/alcalc\/agh130","article-title":"Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician","volume":"40","author":"Ameisen","year":"2005","journal-title":"Alcohol Alcohol"},{"key":"2023091106383942000_ref8","volume-title":"The Alcohol Use Disorders Identification Test. Guidelines for Use in Primary Health Care","author":"Babor","year":"1992"},{"key":"2023091106383942000_ref9","volume-title":"Manual for the Beck Depression Inventory-II","author":"Beck","year":"1996"},{"key":"2023091106383942000_ref10","first-page":"46","article-title":"Baclofen: a game changer in the treatment of alcohol dependence","volume":"55","author":"Brink","year":"2020","journal-title":"Alcohol Alcohol"},{"key":"2023091106383942000_ref11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/acps.12905","article-title":"Baclofen for alcohol use disorder-a systematic meta-analysis","volume":"138","author":"Bschor","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"2023091106383942000_ref12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/mol.63.1.53","article-title":"Withdrawal from chronic intermittent ethanol treatment changes subunit composition, reduces synaptic function, and decreases behavioral responses to positive allosteric modulators of GABAA receptors","volume":"63","author":"Cagetti","year":"2003","journal-title":"Mol Pharmacol"},{"key":"2023091106383942000_ref13","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3389\/fpsyt.2018.00773","article-title":"Baclofen and the alcohol withdrawal syndrome-a short review","volume":"9","author":"Cooney","year":"2019","journal-title":"Front Psych"},{"key":"2023091106383942000_ref14","first-page":"72","article-title":"A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome","volume":"39","author":"Girish","year":"2016","journal-title":"Biom J"},{"key":"2023091106383942000_ref15","doi-asserted-by":"crossref","first-page":"652","DOI":"10.4103\/psychiatry.IndianJPsychiatry_325_19","article-title":"Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome","volume":"61","author":"Gulati","year":"2019","journal-title":"Indian J Psych"},{"key":"2023091106383942000_ref16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/187152710790966614","article-title":"Effectiveness and safety of baclofen in the treatment of alcohol dependent patients","volume":"9","author":"Leggio","year":"2010","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"2023091106383942000_ref17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1152\/jn.90484.2008","article-title":"Tolerance to sedative\/hypnotic actions of GABAergic drugs correlates with tolerance to potentiation of extrasynaptic tonic currents of alcohol-dependent rats","volume":"102","author":"Liang","year":"2009","journal-title":"J Neurophysiol"},{"key":"2023091106383942000_ref18","first-page":"CD008502","article-title":"Baclofen for alcohol withdrawal","volume":"11","author":"Liu","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2023091106383942000_ref19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jhm.928","article-title":"Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial","volume":"6","author":"Lyon","year":"2011","journal-title":"J Hosp Med"},{"key":"2023091106383942000_ref20","first-page":"CD012557","article-title":"Baclofen for alcohol use disorders","volume":"2018","author":"Minozzi","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2023091106383942000_ref21","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.2018.13","article-title":"Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial","volume":"212","author":"Morley","year":"2018","journal-title":"Br J Psychiatry"},{"key":"2023091106383942000_ref22","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.euroneuro.2015.04.002","article-title":"High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial","volume":"25","author":"M\u00fcller","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"2023091106383942000_ref23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.amjms.2021.10.003","article-title":"Outcomes of Minnesota Detoxification Scale (MINDS) assessment with high-dose front loading diazepam treatment for alcohol withdrawal in hospitalized patients","volume":"363","author":"Patel","year":"2022","journal-title":"Am J Med Sci"},{"key":"2023091106383942000_ref24","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.14309\/ajg.0000000000000340","article-title":"Alcohol consumption and risk of liver cirrhosis: a systematic review and meta-analysis","volume":"114","author":"Roerecke","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2023091106383942000_ref25","first-page":"VE01\u20137","article-title":"Alcohol withdrawal syndrome: benzodiazepines and beyond","volume":"9","author":"Sachdeva","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"2023091106383942000_ref26","first-page":"22","article-title":"The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"2023091106383942000_ref27","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","article-title":"Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar)","volume":"84","author":"Sullivan","year":"1989","journal-title":"Br J Addiction"},{"key":"2023091106383942000_ref28","doi-asserted-by":"crossref","first-page":"eaaz4112","DOI":"10.1126\/scisignal.aaz4112","article-title":"The GABAB receptor mediates neuroprotection by coupling to G13","volume":"14","author":"Wang","year":"2021","journal-title":"Sci Signal"}],"container-title":["Alcohol and Alcoholism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/alcalc\/article-pdf\/58\/5\/565\/51471382\/agad050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/alcalc\/article-pdf\/58\/5\/565\/51471382\/agad050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T06:38:55Z","timestamp":1694414335000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/alcalc\/article\/58\/5\/565\/7234268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,7,31]]},"published-print":{"date-parts":[[2023,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/alcalc\/agad050","relation":{},"ISSN":["0735-0414","1464-3502"],"issn-type":[{"value":"0735-0414","type":"print"},{"value":"1464-3502","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,7,31]]}}}